Sponsored by
This is an interesting research project. In theory, PI3Kinase Inhibitors should work well on brain tumors but in the past, results were not great. This project uses a new drug that can cross the blood brain barrier, and combines it with an immune checkpoint inhibitor. Checkpoint inhibitors by themselves have not shown much success in brain tumors either. The research proposes that this drug will increase the immunogenicity of the tumor, allowing the immune checkpoint inhibitor to work better.
We have awarded a research grant in the amount of $40,000 to Dr. Ekokobe Fonkem at Medical College of Wisconsin for the project titled: "Combination of PI3Kinase Inhibitors with Immune Check Point Inhibition as a Potential Therapeutic Target for DIPG". This is for pre-clinical research of the drug GCT007, which is a new, blood brain barrier penetrant PI3Kinase Inhibitors! This grant was given from our DIPG All-In-Initiative fund!